Drug–protein binding: a critical review of analytical tools

Vuignier, Karine; Schappler, Julie; Veuthey, Jean-Luc; Carrupt, Pierre-Alain; Martel, Sophie
September 2010
Analytical & Bioanalytical Chemistry;Sep2010, Vol. 398 Issue 1, p53
Academic Journal
The extent of drug binding to plasma proteins, determined by measuring the free active fraction, has a significant effect on the pharmacokinetics and pharmacodynamics of a drug. It is therefore highly important to estimate drug-binding ability to these macromolecules in the early stages of drug discovery and in clinical practice. Traditionally, equilibrium dialysis is used, and is presented as the reference method, but it suffers from many drawbacks. In an attempt to circumvent these, a vast array of different methods has been developed. This review focuses on the most important approaches used to characterize drug–protein binding. A description of the principle of each method with its inherent strengths and weaknesses is outlined. The binding affinity ranges, information accessibility, material consumption, and throughput are compared for each method. Finally, a discussion is included to help users choose the most suitable approach from among the wealth of methods presented. [Figure not available: see fulltext.]


Related Articles

  • The Clinical Relevance of Plasma Protein Binding Changes. Roberts, Jason A.; Pea, Federico; Lipman, Jeffrey // Clinical Pharmacokinetics;2013, Vol. 52 Issue 1, p1 

    Controversy reigns as to how protein binding changes alter the time course of unbound drug concentrations in patients. Given that the unbound concentration is responsible for drug efficacy and potential drug toxicity, this area is of significant interest to clinicians and academics worldwide....

  • Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. Patel, Indravadan H.; Zhang, Xiaoping; Nieforth, Keith; Salgo, Miklos; Buss, Neil // Clinical Pharmacokinetics;2005, Vol. 44 Issue 2, p175 

    Enfuvirtide, the first fusion inhibitor approved for the treatment of HIV-1 infection, is a synthetic peptide that binds to HIV-1 glycoprotein 41, blocking the fusion of viral and cellular membranes. When administered subcutaneously at the recommended dose of 90mg twice daily with optimised...

  • Do We Need to Optimize Plasma Protein and Tissue Binding in Drug Discovery? Liu, Xingrong; Chen, Cuiping; Hop, Cornelis E. C. A. // Current Topics in Medicinal Chemistry;Feb2011, Vol. 11 Issue 4, p450 

    It is a commonly accepted assumption that only unbound drug molecules are available to interact with their targets. In order to achieve high unbound plasma drug concentration, it seems obvious to design compounds with low plasma protein binding. Similarly to achieve high unbound tissue...

  • Plasma Protein Binding in Drug Discovery and Development. Howard, Monique L.; Hill, John J.; Galluppi, Gerald R.; McLean, Matthew A. // Combinatorial Chemistry & High Throughput Screening;Feb2010, Vol. 13 Issue 2, p170 

    This review describes methods for quantifying the binding of small molecule drug candidates to plasma proteins and the application of these methods in drug discovery and development. Particular attention is devoted to methods amenable to medium-to-high throughput analysis and those well suited...

  • Influence of Burns on Pharmacokinetics and Pharmacodynamics of Drugs Used in the Care of Burn Patients. Blanchet, Benoit; Jullien, Vincent; Vinsonneau, Christophe; Tod, Michel // Clinical Pharmacokinetics;2008, Vol. 47 Issue 10, p635 

    The pharmacokinetics and pharmacodynamics of drugs are significantly altered in the burn patient, and the bum patient population shows wide inter- and intraindividual variation in drug handling. Bum injury evolves in two phases. The first phase corresponds to the bum shock, which occurs during...

  • Nonclinical Pharmacodynamics, Pharmacokinetics, and Safety of BOL-303224-A, a Novel Fluoroquinolone Antimicrobial Agent for Topical Ophthalmic Use. Ward, Keith W.; Lepage, Jean-François; Driot, Jean-Yves // Journal of Ocular Pharmacology & Therapeutics;Jun2007, Vol. 23 Issue 3, p243 

    BOL-303224-A is a novel fluoroquinolone that has never been used systemically and that possesses structural modifications intended to improve its potency compared to other fluoroquinolones. This investigation was conducted to evaluate the nonclinical pharmacokinetics, safety, and...

  • Plasma / Serum Protein Binding Determinations. Banker, Michael J.; Clark, Tracey H. // Current Drug Metabolism;Nov2008, Vol. 9 Issue 9, p854 

    The binding of a drug to serum or plasma proteins enables the transport of drugs via the blood to sites of action throughout the body. For expediency we will use serum proteins throughout this discussion with the understanding that one can substitute the term plasma proteins in all experimental...

  • Clinical Pharmacokinetic and Pharmacodynamic Profile of the HIV Integrase Inhibitor Elvitegravir.  // Clinical Pharmacokinetics;2011, Vol. 50 Issue 4, p229 

    No abstract available.

  • Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Belatacept in Adult Kidney Transplant Recipients. Shen, Jinshan; Townsend, Robert; You, Xiaoli; Shen, Yun; Zhan, Ping; Zhou, Zexun; Geng, Dong; Wu, Dianna; McGirr, Nadia; Soucek, Kathleen; Proszynski, Elizabeth; Pursley, Janice; Masson, Eric // Clinical Drug Investigation;Feb2014, Vol. 34 Issue 2, p117 

    Background and Objectives: Belatacept is a first-in-class, selective co-stimulation blocker recently approved for the prophylaxis of organ rejection in adult kidney transplant recipients. The objective of this study was to report the pharmacokinetics, pharmacodynamics, and immunogenicity of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics